Juliannie Herrera

Medical College of Wisconsin

*This is an algorithmically generated author record based on publicly available information.

See Latest Publications

See Most Cited Publications

ORCID Profile

Google Scholar

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Medical College of Wisconsin

Research Subjects

Research Interests

Juliannie Herrera has a total of 41 co-authors. Here are the top co-authors by number of shared publications:

Aniko Szabo
Medical College of Wisconsin
21 shared publications
Daniel Dorbin
Medical College of Wisconsin 1 Department of Biochemistry, LaBahn Pancreatic Cancer Program Milwaukee, Wisconsin
21 shared publications
Douglas B. Evans
Department of Surgery, Medical College of Wisconsin, Milwaukee, WI 53226, USA
21 shared publications
G. Aaron Hobbes
Department of Biochemistry and Molecular Biology, Medical University of South Carolina, Charleston, South Carolina
21 shared publications
John Fairbanks Langenheim
Thomas Jefferson University 6 Department of Pharmacology, Physiology, and Cancer Biology Philadelphia, Pennsylvania
21 shared publications
Mandana Kamgar
Mary Ann and Charles LaBahn Pancreatic Cancer Program, Medical College of Wisconsin, Milwaukee, WI 53226, USA
21 shared publications

Latest Publications

Sort by

Open Access
Website
Google Scholar
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from Allele-Specific Mechanisms Guide Salvage Therapy to Overcome Daraxonrasib Resistance in Pancreatic Cancer
by Daniel Dorbin, Juliannie Herrera, Raven Davidson, Naveen Kumar Chandrashekar, Gabrielle Scheuber, Priyanga Jayakrishnan, Christabelle Rajesh, Grayson Johnson, Jason Yuan, Matthew A. Sochor, et al.
Figure S1. Role of KRASMUT-SOS axis in MAPK signaling
Website
Google Scholar
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open Access
Figure S1 from Allele-Specific Mechanisms Guide Salvage Therapy to Overcome Daraxonrasib Resistance in Pancreatic Cancer
by Daniel Dorbin, Juliannie Herrera, Raven Davidson, Naveen Kumar Chandrashekar, Gabrielle Scheuber, Priyanga Jayakrishnan, Christabelle Rajesh, Grayson Johnson, Jason Yuan, Matthew A. Sochor, et al.
Figure S1. Role of KRASMUT-SOS axis in MAPK signaling
Open Access
Website
Google Scholar
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from Allele-Specific Mechanisms Guide Salvage Therapy to Overcome Daraxonrasib Resistance in Pancreatic Cancer
by Daniel Dorbin, Juliannie Herrera, Raven Davidson, Naveen Kumar Chandrashekar, Gabrielle Scheuber, Priyanga Jayakrishnan, Christabelle Rajesh, Grayson Johnson, Jason Yuan, Matthew A. Sochor, et al.
Figure S2. Ex-vivo organotypic slice culture methodology
Website
Google Scholar
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open Access
Figure S2 from Allele-Specific Mechanisms Guide Salvage Therapy to Overcome Daraxonrasib Resistance in Pancreatic Cancer
by Daniel Dorbin, Juliannie Herrera, Raven Davidson, Naveen Kumar Chandrashekar, Gabrielle Scheuber, Priyanga Jayakrishnan, Christabelle Rajesh, Grayson Johnson, Jason Yuan, Matthew A. Sochor, et al.
Figure S2. Ex-vivo organotypic slice culture methodology
Open Access
Website
Google Scholar
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from Allele-Specific Mechanisms Guide Salvage Therapy to Overcome Daraxonrasib Resistance in Pancreatic Cancer
by Daniel Dorbin, Juliannie Herrera, Raven Davidson, Naveen Kumar Chandrashekar, Gabrielle Scheuber, Priyanga Jayakrishnan, Christabelle Rajesh, Grayson Johnson, Jason Yuan, Matthew A. Sochor, et al.
Figure S3. RAS inhibitor resistance
Website
Google Scholar
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open Access
Figure S3 from Allele-Specific Mechanisms Guide Salvage Therapy to Overcome Daraxonrasib Resistance in Pancreatic Cancer
by Daniel Dorbin, Juliannie Herrera, Raven Davidson, Naveen Kumar Chandrashekar, Gabrielle Scheuber, Priyanga Jayakrishnan, Christabelle Rajesh, Grayson Johnson, Jason Yuan, Matthew A. Sochor, et al.
Figure S3. RAS inhibitor resistance
Open Access
Website
Google Scholar
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from Allele-Specific Mechanisms Guide Salvage Therapy to Overcome Daraxonrasib Resistance in Pancreatic Cancer
by Daniel Dorbin, Juliannie Herrera, Raven Davidson, Naveen Kumar Chandrashekar, Gabrielle Scheuber, Priyanga Jayakrishnan, Christabelle Rajesh, Grayson Johnson, Jason Yuan, Matthew A. Sochor, et al.
Figure S5. Characterization of toroid integrity by orthogonal methods
Website
Google Scholar
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open Access
Figure S5 from Allele-Specific Mechanisms Guide Salvage Therapy to Overcome Daraxonrasib Resistance in Pancreatic Cancer
by Daniel Dorbin, Juliannie Herrera, Raven Davidson, Naveen Kumar Chandrashekar, Gabrielle Scheuber, Priyanga Jayakrishnan, Christabelle Rajesh, Grayson Johnson, Jason Yuan, Matthew A. Sochor, et al.
Figure S5. Characterization of toroid integrity by orthogonal methods
Open Access
Website
Google Scholar
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from Allele-Specific Mechanisms Guide Salvage Therapy to Overcome Daraxonrasib Resistance in Pancreatic Cancer
by Daniel Dorbin, Juliannie Herrera, Raven Davidson, Naveen Kumar Chandrashekar, Gabrielle Scheuber, Priyanga Jayakrishnan, Christabelle Rajesh, Grayson Johnson, Jason Yuan, Matthew A. Sochor, et al.
Figure S4 Patient Tumor Bioprinting
Website
Google Scholar
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open Access
Figure S4 from Allele-Specific Mechanisms Guide Salvage Therapy to Overcome Daraxonrasib Resistance in Pancreatic Cancer
by Daniel Dorbin, Juliannie Herrera, Raven Davidson, Naveen Kumar Chandrashekar, Gabrielle Scheuber, Priyanga Jayakrishnan, Christabelle Rajesh, Grayson Johnson, Jason Yuan, Matthew A. Sochor, et al.
Figure S4 Patient Tumor Bioprinting
Open Access
Website
Google Scholar
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Figure S6 from Allele-Specific Mechanisms Guide Salvage Therapy to Overcome Daraxonrasib Resistance in Pancreatic Cancer
by Daniel Dorbin, Juliannie Herrera, Raven Davidson, Naveen Kumar Chandrashekar, Gabrielle Scheuber, Priyanga Jayakrishnan, Christabelle Rajesh, Grayson Johnson, Jason Yuan, Matthew A. Sochor, et al.
Figure S6. Sensitivity to trametinib
Website
Google Scholar
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open Access
Figure S6 from Allele-Specific Mechanisms Guide Salvage Therapy to Overcome Daraxonrasib Resistance in Pancreatic Cancer
by Daniel Dorbin, Juliannie Herrera, Raven Davidson, Naveen Kumar Chandrashekar, Gabrielle Scheuber, Priyanga Jayakrishnan, Christabelle Rajesh, Grayson Johnson, Jason Yuan, Matthew A. Sochor, et al.
Figure S6. Sensitivity to trametinib
Open Access
Website
Google Scholar
- 31 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Mutant and Wild-Type RAS Cross-talk and Stoichiometric Deficiencies Are Determinants of Sensitivity to Targeted Therapies in KRASG12R Pancreatic Ductal Adenocarcinoma
by Mandana Kamgar, G. Aaron Hobbs, Raven Davidson, Daniel Dorbin, Juliannie Herrera, John F. Langenheim, Rachel A. Burge, Mohammed Aldakkak, Ryan D. Conrardy, Aniko Szabo, et al.
Mutant KRAS allele dependent activation of WT-RAS
Website
Google Scholar
- 31 August 2026
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Figure 2 from Mutant and Wild-Type RAS Cross-talk and Stoichiometric Deficiencies Are Determinants of Sensitivity to Targeted Therapies in KRASG12R Pancreatic Ductal Adenocarcinoma
by Mandana Kamgar, G. Aaron Hobbs, Raven Davidson, Daniel Dorbin, Juliannie Herrera, John F. Langenheim, Rachel A. Burge, Mohammed Aldakkak, Ryan D. Conrardy, Aniko Szabo, et al.
Mutant KRAS allele dependent activation of WT-RAS
Open Access
Website
Google Scholar
- 31 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from Mutant and Wild-Type RAS Cross-talk and Stoichiometric Deficiencies Are Determinants of Sensitivity to Targeted Therapies in KRASG12R Pancreatic Ductal Adenocarcinoma
by Mandana Kamgar, G. Aaron Hobbs, Raven Davidson, Daniel Dorbin, Juliannie Herrera, John F. Langenheim, Rachel A. Burge, Mohammed Aldakkak, Ryan D. Conrardy, Aniko Szabo, et al.
Kaplan-Meier estimates of progression-free survival
Website
Google Scholar
- 31 August 2026
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Figure 3 from Mutant and Wild-Type RAS Cross-talk and Stoichiometric Deficiencies Are Determinants of Sensitivity to Targeted Therapies in KRASG12R Pancreatic Ductal Adenocarcinoma
by Mandana Kamgar, G. Aaron Hobbs, Raven Davidson, Daniel Dorbin, Juliannie Herrera, John F. Langenheim, Rachel A. Burge, Mohammed Aldakkak, Ryan D. Conrardy, Aniko Szabo, et al.
Kaplan-Meier estimates of progression-free survival
Open Access
Website
Google Scholar
- 31 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Mutant and Wild-Type RAS Cross-talk and Stoichiometric Deficiencies Are Determinants of Sensitivity to Targeted Therapies in KRASG12R Pancreatic Ductal Adenocarcinoma
by Mandana Kamgar, G. Aaron Hobbs, Raven Davidson, Daniel Dorbin, Juliannie Herrera, John F. Langenheim, Rachel A. Burge, Mohammed Aldakkak, Ryan D. Conrardy, Aniko Szabo, et al.
Supporting Data for Isogenic cells
Website
Google Scholar
- 31 August 2026
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Figure 1 from Mutant and Wild-Type RAS Cross-talk and Stoichiometric Deficiencies Are Determinants of Sensitivity to Targeted Therapies in KRASG12R Pancreatic Ductal Adenocarcinoma
by Mandana Kamgar, G. Aaron Hobbs, Raven Davidson, Daniel Dorbin, Juliannie Herrera, John F. Langenheim, Rachel A. Burge, Mohammed Aldakkak, Ryan D. Conrardy, Aniko Szabo, et al.
Supporting Data for Isogenic cells
Open Access
Website
Google Scholar
- 31 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Mutant and Wild-Type RAS Cross-talk and Stoichiometric Deficiencies Are Determinants of Sensitivity to Targeted Therapies in KRASG12R Pancreatic Ductal Adenocarcinoma
by Mandana Kamgar, G. Aaron Hobbs, Raven Davidson, Daniel Dorbin, Juliannie Herrera, John F. Langenheim, Rachel A. Burge, Mohammed Aldakkak, Ryan D. Conrardy, Aniko Szabo, et al.
Patient, tumor and treatment characteristics
Website
Google Scholar
- 31 August 2026
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Table 1 from Mutant and Wild-Type RAS Cross-talk and Stoichiometric Deficiencies Are Determinants of Sensitivity to Targeted Therapies in KRASG12R Pancreatic Ductal Adenocarcinoma
by Mandana Kamgar, G. Aaron Hobbs, Raven Davidson, Daniel Dorbin, Juliannie Herrera, John F. Langenheim, Rachel A. Burge, Mohammed Aldakkak, Ryan D. Conrardy, Aniko Szabo, et al.
Patient, tumor and treatment characteristics

Show all